Insights 18th August 2020
CSL (ASX:CSL) Reporting Season Results
Global biotech company and biggest company on the ASX, CSL (ASX:CSL), reported its full year financial results, here’s what you need to know.
Net profit after tax (NPAT) gained 9.6% to US$2.1b, following growth in its immunoglobulin portfolio, successful haemophilia portfolio and a transition to its own distribution model in China. This results was in line with market expectations.
CSL reported a revenue increase of 7% to US$9.2b, noting that the biotech giant had no material revenue impact to date as a result of COVID-19. Earnings before interest, tax, depreciation and amortisation (EBITDA) gained 9% to US$3.1b.
CSL reported a full year dividend of US$2.02 per share including the final dividend of US$1.07 per share unfranked, a 9% increase from last year.